Abratt R P, Willcox P A, Hewitson R H
Cancer Chemother Pharmacol. 1987;20(1):83-4. doi: 10.1007/BF00252967.
Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to patients with limited disease after chemotherapy. In limited-disease and extensive-disease patients the median survival was 12 and 6 months respectively. The 2-year survival rate (life table) in limited-disease patients was 26%. Treatment morbidity was low. A prospective randomised trial is being undertaken to further evaluate the role of oral etoposide in combination chemotherapy.
连续63例肺小细胞癌患者接受了六个周期的治疗，治疗方案为依托泊苷120mg/m²静脉注射第1天，第2 - 5天口服；阿霉素40mg/m²静脉注射第1天；长春新碱1.4mg/m²静脉注射第1天，每3周为一个周期。化疗后对局限性疾病患者进行瘤床照射。局限性疾病和广泛性疾病患者的中位生存期分别为12个月和6个月。局限性疾病患者的2年生存率（生命表法）为26%。治疗的发病率较低。正在进行一项前瞻性随机试验以进一步评估口服依托泊苷在联合化疗中的作用。
